L’importanza del vaccino anti Covid-19 nei pazienti affetti da malattia del rene policistico autosomico dominante dell’adulto (ADPKD)
Parole chiave:ADPKD patients, SARS-CoV-2 (Covid-19), Vaccine
The SARS-CoV-2 (Covid-19) infection affected about 106 million people worldwide and the total amount of casualties now sits at a staggering 2 millions.
Chronic Kidney Disease (CKD) emerged as the first risk factor in worst patients, not considering old age. Kidney disease and acute kidney injury have been correlated with a higher chance of death. This combination of CKD and higher Covid-19 related mortality requires immediate response from a prevention point of view at first and then from a therapeutic one.
There is not a clear relation between Covid-19 and ADPKD. What can be inferred is the following: Covid uses the ACE2 receptors on cell membranes to “lock on” its target. It is well-established in fact that the RAAS is more active in ADPKD patients and it may represent an additional risk factor for these patients.
At the moment three Covid-19 vaccines have been approved, and two of them have been already administered, such as Pfizer BioNTech and Moderna, sharing the same mechanism. AstraZeneca released a third option. All of them are completely safe and reliable, each one with its own feature.
Therefore, considering how delicate ADPKD patients are, vaccination is strongly recommended.
Rashedi J, Mahdavi Poor B, Asgharzadeh V, et al. Risk Factors for COVID-19. Infez Med. 2020;28(4):469-474. PMID:33257620
Adapa S, Chenna A, Balla M, et al. COVID-19 pandemic causing acute kidney injury and impact on patients with chronic kidney disease and renal transplantation. J Clin Med Res. 2020;12(6):352-361. https://doi.org/10.14740/jocmr4200 PMID: 32587651
Gagliardi I, Patella G, Michael A, Serra R, Provenzano M, Andreucci M. COVID-19 and the kidney: from epidemiology to clinical practice. J Clin Med. 2020;9(8):2506. Online https://doi.org/10.3390/jcm9082506 PMID: 32759645
Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-637. https://doi.org/10.1002/path.1570 PMID:15141377
Stephens JR, Stümpfle R, Patel P, et al. Analysis of Critical Care Severity of Illness Scoring Systems in Patients With Coronavirus Disease 2019: A Retrospective Analysis of Three U.K. ICUs. Crit Care Med. 2021;49(1):e105-e107. https://doi.org/10.1097/CCM.0000000000004674PMID:32991357
Fominskiy EV, Scandroglio AM, Monti G, et al; COVID-BioB Study Group. Prevalence, Characteristics, Risk Factors, and Outcomes of Invasively Ventilated COVID-19 Patients with Acute Kidney Injury and Renal Replacement Therapy. Blood Purif. 2021;50(1):102-109. https://doi.org/10.1159/000508657 PMID:32659757
Quintaliani G, Reboldi G, Di Napoli A, et al; Italian Society of Nephrology COVID-19 Research Group. Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID-19 pandemic: survey of the Italian Society of Nephrology. J Nephrol. 2020;33(4):725-736. https://doi.org/10.1007/s40620-020-00794-1 PMID:32621109
Sciarrone Alibrandi MT, Vespa M. Kidney, ADPKD and Covid-19: the double role of renal fragility. G Clin Nefrol E Dialisi. 2020;32(1):99-101. https://doi.org/10.33393/gcnd.2020.2165
Polack FP, Thomas SJ, Kitchin N, et al; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. https://doi.org/10.1056/NEJMoa2034577 PMID:33301246
Anderson EJ, Rouphael NG, Widge AT, et al; mRNA-1273 Study Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020;383(25):2427-2438. https://doi.org/10.1056/NEJMoa2028436 PMID:32991794
Glanville D. COVID-19 vaccines: key facts. European Medicines Agency. 2020. Online https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-key-facts
Vaccini a mRNA | Agenzia Italiana del Farmaco. Online https://aifa.gov.it/vaccini-mrna
Vaccini a vettore virale | Agenzia Italiana del Farmaco. Online https://aifa.gov.it/vaccini-vettore-virale
Glanville D. EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU. European Medicines Agency. 2021. Online https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu
Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for Covid-19. Front Immunol. 2020;11:585354. Online https://www.frontiersin.org/articles/10.3389/fimmu.2020.585354/full
Pinho AC. EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU. European Medicines Agency. 2021. Online https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu
Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72-74. https://doi.org/10.1016/S0140-6736(20)32623-4 PMID:33306990
Voysey M, Clemens SAC, Madhi SA, et al; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. https://doi.org/10.1016/S0140-6736(20)32661-1 PMID:33306989
Copyright (c) 2021 Gli autori
Questo lavoro è fornito con la licenza Creative Commons Attribuzione - Non commerciale 4.0 Internazionale.
Gli autori che scelgono il Giornale di Clinica Nefrologica e Dialisi (GCND) per la pubblicazione dei propri contributi si impegnano ad utilizzare la licenza CC-BY-NC 4.0, che consente a terzi di riutilizzare l'articolo senza richiedere permesso purchè l'articolo sia correttamente citato e non sia utilizzato a scopi commerciali.